Nativis
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
13810 SE Eastgate Way Ste 560, Bellevue,...Phone Number
(425) 415-3140Website
www.emulatetx.comRevenue
$9.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Nativis
EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE), to provide safe and effective therapeutic treatments for numerous unmet medical needs.Explore more
Nativis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nativis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Nativis had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Nativis
Check out if Nativis is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nativis has recently received funding, and reach out quickly before it becomes old news!
Nativis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Nativis recently announced quarterly report
Funding: Get notified immidiatlly once Nativis has new funding data
Product Launch: Get notified when Nativis launches new products
Recommended Actions
Reach out to Masked Content who joined Nativis as Masked Content
Find more new buyers
Compare Similar Companies to Nativis
Compare insights from companies similar to Nativis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nativis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nativis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nativis.
Nativis financials insights
Gather financial insights about Nativis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Private Equity
$11.5M
2015
Private Equity
$725K
Private Equity
$9.6M
2017
Private Equity
$10M
Private Equity
$1M
2020
Debt
$150K
Nativis Tech Stack
A closer look at the technologies used by Nativis
See more technologies
Most Recent Scoops
Funding
Nativis has received an SBA PPP loan for $150,000-350,000 from MUFG Union Bank, supporting the retention of 14 jobs.
Executive Move
Nativis has announced the appointment of Andrew Daniels to the company's Board of Directors.
Partnership, Board of Directors
Funding
Nativis recently secured $10 million in a Series A funding round.
Funding
Executive Move
Nativis has announced the appointment of Dr. Daniel Kisner to the company's Board of Directors. As former Chief Executive Officer of Caliper Technologies, Kisner is expected to leverage his pharmaceutical and medical device experience to support the Board's efforts.
Partnership
Analytics & Insights
Nativis News & Media
EMulate Therapeutics Opens Community Investment Round on Wefunder, Offering Public Access to Groundbreaking Digital Therapeutics Platform
Revolutionary ulRFE® Technology Demonstrates Promising Results in Brain Cancer, Mental Health, and Pain Management Without Traditional Drugs or their Side Effects Revolutionary ulRFE® Technology Demonstrates Promising Results in Brain Cancer, Mental Health, and Pain Management Without Traditional Drugs or their Side EffectsEMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model
BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (“Emulate”) announces the Open Journal of Biophysics (OJBIPHY), publisher of over 200 peer-reviewed open access journals, has accepted its manuscript, titled “Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice” for publication. This submission supports independent results in an animal model of Glioblastoma Multiforme (GBM), recently published by Mukthavaram et al. (BioeEMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine
BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine. The authors of the paper (Rajesh Mukthavaram; Pengfei Jiang; Sandra Pastorino; Natsuko Nomura; Feng Lin; Santosh Kesari) tested the effectiveness of the emulation of EMulate’s ulRFE signal of paclitaxel (A1A) and the immuEMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG
BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia. The accepted abstract will be published in SNO’s official journal, Neuro-Oncology, which is now available at https://academic.oup.com/neuro-oncology/supplements. The abstract describes the poster material dev
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nativis
Sign Up For FreeTo access detailed company insights
EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE), to provide safe and effective therapeutic treatments for numerous unmet medical needs.... Read More
